Abstract
The Nasal potential difference measurement is used to measure the voltage across the nasal epithelium, which results from transepithelial ion transport and reflects in part CFTR function. The electrophysiologic abnormality in cystic fibrosis was first described 30 years ago and correlates with features of the CF phenotype. NPD measurement is an important in vivo research and diagnostic tool, and is used to assess the efficacy of new treatments such as gene therapy and ion transport modulators. This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Knowles, M., Gatzy, J., and Boucher, R. (1981) Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med. 305, 1489–1495.
Knowles, M. R., Paradiso, A. M., and Boucher, R. C. (1995) In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6, 445–455.
Middleton, P. G., Geddes, D. M., and Alton, E. W. (1994) Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur. Respir. J. 7, 2050–2056.
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R. et al. (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic fibrosis foundation consensus report. J. Pediatr. 153, S4–S14.
De Boeck, K., Wilschanski, M., Castellani, C., Taylor, C., Cuppens, H., Dodge, J. et al. (2006) Cystic fibrosis: Terminology and diagnostic algorithms. Thorax 61, 627–635.
Knowles, M. R., Hohneker, K. W., Zhou, Z., Olsen, J. C., Noah, T. L., Hu, P. C. et al. (1995) A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333, 823–831.
Noone, P. G., Hohneker, K. W., Zhou, Z., Johnson, L. G., Foy, C., Gipson, C. et al. (2000) Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol. Ther. 1, 105–114.
Middleton, P. G., Caplen, N. J., Gao, X., Huang, L., Gaya, H., Geddes, D. M. et al. (1994) Nasal application of the cationic liposome DC-Chol: DOPE does not alter ion transport, lung function or bacterial growth. Eur. Respir. J. 7, 442–445.
McCarty, N. A., Standaert, T. A., Teresi, M., Tuthill, C., Launspach, J., Kelley, T. J. et al. (2002) A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr. Pulmonol. 33, 90–98.
Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J. et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433–1441.
Kerem, E., Yaacov, Y., Armoni, S. et al. (2008) PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis. Pediatr. Pulmonol. Suppl. 31, 294.
Clancy, J. P., Rowe, S. M., Bebok, Z., Aitken, M. L., Gibson, R., Zeitlin, P. et al. (2007) No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am. J. Respir. Cell. Mol. Biol. 37, 57–66.
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., Moss, R. B., Pilewski, J. M., Rubenstein, R. C., Uluer, A. Z., Aitken, M. L., Freedman, S. D., Rose, L. M., Mayer-Hamblett, N., Dong, Q., Zha, J., Stone, A.J., Olson, E. R., Ordonez, C. L., Campbell, P. W., Ashlock, M. A., and Ramsey, B. W. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991–2003.
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. et al. (2004) Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15, 1255–1269.
Zeitlin, P. L., Boyle, M. P., Guggino, W. B., and Molina, L. (2004) A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 125, 143–149.
Rowe, S. M., Accurso, F., and Clancy, J. P. (2007) Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc. Am. Thorac. Soc. 4, 387–398.
Rowe, S. M., Reeves, G., Young, H. et al. (2008) Correction of sodium transport with nasal administration of the prostasin inhibitor QAU145 in CF subjects. Pediatr. Pulmonol. Suppl. 31, A268.
Rowe, S. M., Miller, S., and Sorscher, E. J. (2005) Cystic fibrosis. N. Engl. J. Med. 352, 1992–2001.
Gatzy, J. T. (1967) Bioelectric properties of the isolated amphibian lung. Am. J. Physiol. 213, 425–431.
Knowles, M. R., Carson, J. L., Collier, A. M., Gatzy, J. T., and Boucher, R. C. (1981) Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am. Rev. Respir. Dis. 124, 484–490.
Knowles, M. R., Buntin, W. H., Bromberg, P. A., Gatzy, J. T., and Boucher, R. C. (1982) Measurements of transepithelial electric potential differences in the trachea and bronchi of human subjects in vivo. Am. Rev. Respir. Dis. 126, 108–112.
Davies, J. C., Davies, M., McShane, D., Smith, S., Chadwick, S., Jaffe, A. et al. (2005) Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 1015–1019.
Anderson, M. P., Gregory, R. J., Thompson, S., Souza, D. W., Paul, S., Mulligan, R. C. et al. (1991) Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253, 202–205.
Li, C., and Naren, A. P. (2005) Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol. Ther. 108, 208–223.
Olivier, K. N., Bennett, W. D., Hohneker, K. W., Zeman, K. L., Edwards, L. J., Boucher, R. C. et al. (1996) Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate ± amiloride in normal human adults. Am. J. Respir. Crit. Care Med. 154, 217–223.
Wilschanski, M., Dupuis, A., Ellis, L., Jarvi, K., Zielenski, J., Tullis, E. et al. (2006) Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am. J. Respir. Crit. Care Med. 174, 787–794.
Fajac, I., Hubert, D., Guillemot, D., Honoré, I., Bienvenu, T., Volter, F. et al. (2004) Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients. Thorax 59, 971–976.
Solomon, G. M., Konstan, M. W., Wilschanski, M., Billings, J., Sermet-Gaudelus, I., Accurso, F., Vermeulen, F., Levin, E., Hathorne, H., Reeves, G., Sabbatini, G., Hill, A., Mayer-Hamblett, N., Ashlock, M., Clancy, J. P., and Rowe, S. M. (2010) An international randomized multicenter comparison of nasal potential difference techniques. Chest 138, 919–928.
Cohen, M., Beamer, J. R., Clancy, J. P. et al. (2008) Centralized production and long term stability of electrolytes and amiloride in solutions for nasal potential difference testing. Pediatr. Pulmonol. Suppl. 31, A275.
Wilschanski, M., Famini, H., Strauss-Liviatan, N., Rivlin, J., Blau, H., Bibi, H. et al. (2001) Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur. Respir. J. 17, 1208–1215.
Sermet-Gaudelus, I., Renouil, M., Fajac, A., Bidou, L., Parbaille, B., Pierrot, S. et al. (2007) In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: A pilot study. BMC Med. 5, 5.
Leal, T., Lebacq, J., Lebecque, P., Cumps, J., and Wallemacq, P. (2003) Modified method to measure nasal potential difference. Clin. Chem. Lab. Med. 41, 61–67.
Ahrens, R. C., Standaert, T. A., Launspach, J., Han, S. H., Teresi, M. E., Aitken, M. L. et al. (2002) Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr. Pulmonol. 33, 142–150.
Yaakov, Y., Kerem, E., Yahav, Y., Rivlin, J., Blau, H., Bentur, L. et al. (2007) Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 132, 1219–1226.
Acknowledgments
The authors are grateful to Michael Knowles for providing a critical review of the material presented and also to Peter Durie for helpful critiques in devising current methods proposed here. Support for this work was provided by the US National Institute of Health grants 1K23DK075788-01 and 1R03DK084110-01 (to S.M.R.), 1P30DK072482-01A1 (to Eric J. Sorscher for infrastructural support) and Cystic Fibrosis Foundation grants CLANCY05Y2 (S.M.R. and J.P.C.). This project was supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; or the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Rowe, S.M., Clancy, J.P., Wilschanski, M. (2011). Nasal Potential Difference Measurements to Assess CFTR Ion Channel Activity. In: Amaral, M., Kunzelmann, K. (eds) Cystic Fibrosis. Methods in Molecular Biology, vol 741. Humana Press. https://doi.org/10.1007/978-1-61779-117-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-61779-117-8_6
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-116-1
Online ISBN: 978-1-61779-117-8
eBook Packages: Springer Protocols